Prognostic Value of Body Composition in Lung Cancer

Marmara University

Status: Completed

Conditions: Body Composition and Non-small Cell Lung Cancer

Treatments: Other: measured of body composition with computed tomography

Study type: Observational

Funder types: Other

Identifiers

NCT05512429

09.2019.1026

Details and patient eligibility

About

The effect of body composition on the survival rate is one of the research topics of interest in cancer patients and gaining attention in the last years. Body mass index is often used a proxy measure of total adiposity and previous studies examining the relationship between BMI and cancer outcomes have been showed distinct results . Obese patients with malignancies such as colorectal, breast, and pancreatic cancers, have been shown to have a worse prognosis than normal-weight patients . Nevertheless, obese patients with non small cell lung cancer(NSCLC) have been observed to have a better clinical outcome than normal/low-weight cancer patients . In this study, we examined the effects of subcutaneous adipose tissue, visceral adipose tissue and skeletal muscle volumes on survival in metastatic NSCLC patients under different treatment regimens. Since there is no standard method for adipose tissue measurement, we evaluated the abdominal cavity with multi-slice and single-slice computed tomography measurements.

Enrollment: 83 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Having a pathological diagnosis of non small cell lung cancer
2. Having a stage-IV disease
3. To have received at least one course of treatment
4. Presence of positron emission tomography /computed tomography (PET/CT) examination before treatment and having it taken in our hospital
5. The data about the study can be accessed in our center.
6. To be over 18 years old

Exclusion criteria

1. Unable to access patients data
2. PET/CT CDs cannot be accessed or are not suitable for evaluation.

Trial design

83 participants in 1 patient group

Stage-IV non small cell lung cancer (NSCLC)

Description:

Eighty-three patients with stage-IV NSCLC who received at least one cycle of platinum based chemotherapy (PBCT) or tyrosine kinase inhibitor (TKI) therapy and who underwent pre treatment fluorodeoxyglucose (FDG)-positron emission tomography (PET) /computed tomography (FDG PET/CT) from June 2012 to February 2019

Treatment:

Other: measured of body composition with computed tomography